We hypothesized that Herceptin-conjugated immunoliposome encapsulating MET can target both HER2+ breast cancer cells and BCSCs via active targeting of a well-known specific receptor and endocytic activity of CSCs, respectively. Here, ERBB2 is linked to breast carcinoma.